Drug Prices: Renegotiate The Deal

The crying game is an apt description of the melodrama now being played out on the Washington stage, with both the Clinton Administration and the pharmaceutical industry crying foul, feeling betrayed, and acting deeply wounded. The performances could simply be dismissed as bad soap opera, were it not for the importance of the issue at the heart of the dispute--drug prices and the need to curtail soaring health-care costs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.